Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Breast Cancer

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Breast Cancer

13 stories · every one Fact-Checked
Iksuda Therapeutics IKS014 HER2-directed antibody-drug conjugate showing preliminary activity in HER2-positive breast cancer.Health TidingsIksuda Reports 50% ORR With IKS014 After T-DXd in HER2+ Breast CancerIksuda Therapeutics reported a 50% objective response rate with its HER2-directed ADC IKS014 in a small group of heavily pretreated HER2-positive breast cancer patients previously treated with trastuzumab…2 Nov 2026 · 4 min read
Fact-Checked
BioNTech and DualityBio’s trastuzumab pamirtecan in the DYNASTY-Breast02 phase 3 breast cancer trialClinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Cancer TrialBioNTech and DualityBio’s phase 3 DYNASTY-Breast02 trial met its primary PFS endpoint for trastuzumab pamirtecan in HR-positive/HER2-low metastatic breast cancer.29 Oct 2026 · 4 min read
Fact-Checked
Prelude Therapeutics’ investigational KAT6A degrader PRT13722 in combination with abemaciclib and imlunestrant for HR-positive, HER2-negative breast cancer.Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Breast CancerPrelude Therapeutics and Lilly will evaluate PRT13722 with abemaciclib and imlunestrant in a Phase 1 trial for HR+/HER2− breast cancer…13 Oct 2026 · 3 min read
Fact-Checked
TUKYSA tucatinib approved for first-line maintenance in HER2-positive metastatic breast cancerNew Drug ApprovalFDA Approves TUKYSA as First-Line Maintenance in Breast CancerPfizer’s TUKYSA (tucatinib) gains FDA approval for first-line maintenance in HER2-positive metastatic breast cancer after induction therapy, following an 8.6-month improvement in median progression-free survival in HER2CLIMB-05.8 Oct 2026 · 4 min read
Fact-Checked
Datroway (datopotamab deruxtecan) approved by the European Commission for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 immunotherapy.New Drug ApprovalEU Approves Datroway for Metastatic Triple-Negative Breast CancerThe European Commission has approved Datroway (datopotamab deruxtecan) for the first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor…31 Jul 2026 · 4 min read
Fact-Checked
AstraZeneca's Etcamah (camizestrant) receives European Commission approval for ESR1-mutated ER-positive, HER2-negative advanced breast cancer based on the Phase 3 SERENA-6 trial.New Drug ApprovalAstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated HR-Positive Advanced Breast CancerThe European Commission has approved AstraZeneca’s Etcamah (camizestrant) with CDK4/6 inhibitors for adults with ESR1-mutated ER-positive, HER2-negative advanced breast cancer.23 Jul 2026 · 4 min read
Fact-Checked
Celcuity submits FDA sNDA for REVTORPYK gedatolisib in PIK3CA-mutant HR-positive HER2-negative advanced breast cancerNew Drug ApprovalFDA Approves REVTORPYK for PIK3CA Wild-Type HR+/HER2- Advanced Breast CancerThe FDA has approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive/HER2-negative locally advanced or metastatic breast cancer after endocrine therapy.15 Jul 2026 · 4 min read
Fact-Checked
Gemini_Generated_Image_8klh0w8klh0w8klhMergers & AcquisitionsAstex Signs Breast Cancer Drug Discovery Deal with GenentechAstex Pharmaceuticals has signed an exclusive global research collaboration and licensing agreement with Genentech to advance a novel small-molecule breast cancer program targeting a key cell-cycle regulator.6 Jul 2026 · 3 min read
Fact-Checked
Screenshot 2026-06-03 143831Clinical TrialsCelcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast CancerCelcuity Celcuity’s Phase 3 VIKTORIA-1 trial shows gedatolisib-based regimens doubled progression-free survival versus alpelisib in HR+/HER2-, PIK3CA-mutated advanced breast cancer…3 Jun 2026 · 3 min read
Fact-Checked
309305-1_11zon-scaled-rk9pc55zq2uuzilsrc1stgidw6oazbjn30q6dz6u54Health TidingsRoche’s Giredestrant Wins FDA Priority Review for Early Breast CancerRoche has advanced its breast cancer pipeline with FDA acceptance of a Priority Review NDA for giredestrant in stage I–III ER-positive/HER2-negative disease.2 Jun 2026 · 3 min read
Fact-Checked
Mobile electronic traffic sign with inscription Expect delays placed on road in city street in evening timeHealth TidingsFDA Extends Review of Camizestrant in ESR1‑Mutant Breast CancerThe FDA has delayed its decision on AstraZeneca’s camizestrant combination for ESR1‑mutant HR‑positive, HER2‑negative advanced breast cancer, extending the PDUFA timeline after requesting further analyses from the Phase…27 May 2026 · 3 min read
Fact-Checked
original (2)_11zonHealth TidingsCHMP Issues Positive Opinion for Camizestrant in ESR1‑Mutant Breast CancerThe European Medicines Agency’s CHMP has recommended camizestrant in combination with a CDK4/6 inhibitor for patients with ER+/HER2‑ advanced breast cancer who develop ESR1 mutations during first‑line endocrine…23 May 2026 · 3 min read
Fact-Checked
Page 1 of 2